

Immunopathologia Persa

DOI:10.34172/ipp.2022.xx

A systematic review and meta-analysis on the association between lymphocyte subsets and the severity of COVID-19



Hojat Dehghanbanadaki^{1,2#®}, Hossein Aazami^{3,4#®}, Mahya Shabani^{5®}, Dorsa Amighi^{5®}, Farhad Seif^{6®}, Ali Zare Dehnavi^{5®}, Abdolkarim Hajighadery^{7®}, Mohammad-Mehdi Mehrabi Nejad^{7®}, Mohammad Ghafouri^{5®}, Nima Hajizadeh⁸[®], Fateme Abedin^{5®}, Zahra Hajizadeh^{8®}, Mehrdad Heravi^{9®}, Parsa Panahi^{10®}, Ali Kabir^{11*®}

¹Metabolomics and Genomics Research Center Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

²Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran ³Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

⁴Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

⁵Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁶Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran

⁷Department of Radiology, Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical

Sciences, Tehran, Iran

⁸School of Medicine, Iran University of Medical Sciences, Tehran, Iran

9School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

¹⁰Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

¹¹Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran

#Hojat Dehghanbanadaki and Hossein Aazami contributed equally to this work.

*Correspondence to Ali Kabir, MD, MPH, PhD; Email: kabir.a@iums.ac.ir,

aikabir@yahoo.com

Received 1 Oct. 2021 Accepted 7 Nov. 2021 Published online 6 Dec. 2021

Keywords: Lymphocyte, Severity, Meta-analysis, SARS-CoV-2, COVID-19



Citation:

Dehghanbanadaki H, Aazami H, Shabani M, Amighi D, Seif F, Zare Dehnavi A, et al. A systematic review and meta-analysis on the association between lymphocyte subsets and the severity of COVID-19. Immunopathol Persa. 2022;x(x):e0x. DOI:10.34172/ipp.2022. xx.

Abstract

Introduction: Prominent prognostic parameters that reflect the severity of coronavirus disease 2019 (COVID-19) to adopt an appropriate therapeutic approach are not fully identified. This systematic review and meta-analysis aimed to explore the association between lymphocyte variation and disease severity in COVID-19 individuals. **Methods:** We searched Web of Science, Scopus, PubMed, EMBASE and WHO website to retrieve studies investigating lymphocyte subset counts in non-severe and severe cases of COVID-19. The pooled standardized mean difference (SMD) between two groups and the pooled average count of each lymphocyte subset were assessed by employing a random-effect model.

Results: Thirty-nine investigations on 5,087 participants, including 3,578 non-severe patients and 1,509 severe patients, were included. The pooled analysis showed that non-severe patients had higher total T lymphocytes (SMD = 1.01; 95% CI: 0.82, 1.20; I² = 75.7%), T helper cells (SMD = 1.07; 95% CI: 0.85, 1.28; I² = 85.4%), T cytotoxic cells (SMD = 1.07; 95% CI: 0.82, 1.32; I² = 87.1%), B cells (SMD = 0.72; 95% CI: 0.45, 0.98; I² = 79.7%), and natural killer cells (SMD = 0.65; 95% CI: 0.47, 0.84; I² = 63.1%) than severe patients and the average count of the corresponding lymphocyte signatures in non-severe patients/severe patients were 878.88/448.40, 493.12/268.96, 311.91/158.91, 177.09/110.37, and 155.02/103.09 cells/µL, respectively.

Conclusion: Lymphopenia may be a dilemma in COVID-19 management because over-activation of lymphocytes may lead to cytokine storm or acute respiratory distress syndrome (ARDS). In contrast, lymphopenia may increase SARS-CoV-2 amplification and COVID-19 severity. Therefore, novel therapies targeting lymphocyte proliferation or contraction may counterbalance lymphocyte counts in these patients.

Introduction

In December 2019, individuals infected with a novel kind of viral pneumonia were reported in Wuhan, China. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified to cause coronavirus disease 2019 (COVID-19) (1). The clinical manifestations of most patients with COVID-19 range from mild to severe symptoms. Lymphocyte subsets play important roles in the integrity and regulation of the immune system. Viral infections, especially SARS-CoV-2 infection, can dysregulate lymphocyte counts and function. Patients with COVID-19 showed

Copyright © 2022 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

http www.immunopathol.com

Key point

This meta-analysis showed reduced level of total T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells in severe cases of COVID-19 compared to non-severe cases. By considering the decrease or increase of these immune cells in patients with severe COVID-19, the appropriate diagnosis, prognosis, follow-up, targeted therapy, and response to the treatment will be more achievable in these patients.

contradictory patterns of natural killer (NK) cells, CD4+ T cells, CD8+T cells, and B cells (2,3). T cells play an important role in virus eradication where CD4+ T cells (T helper cells) help other immune cells, especially activated CD8+ T cells (T cytotoxic cells) produce cytokines and eliminate molecules to combat the virus. Moreover, CD4+ T cells help B cells and macrophages enhance their capacity to eliminate pathogens by antibody production and phagocytosis, respectively (3). Viral infections usually induce lymphocytosis, especially CD8+ T cell responses; however, contradictory findings have been reported regarding lymphopenia and interferonopathy in individuals with severe COVID-19; therefore, this systematic review and meta-analysis aimed to explore the association among lymphocyte variation and disease severity in COVID-19 patients.

Methods

Protocol registration

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for this systematic review and the research question was determined with PICO framework as follows: what is the alteration of lymphocyte subsets (O) in severe patients (I) compared to non-severe patients (C) with COVID-19 infection (P).

Search strategy and study selection

PubMed, Web of Science, Scopus, EMBASE and WHO were searched for related studies on "lymphocyte", "severity", and "COVID-19" from the emergence of COVID-19 to 1 April 2021. Two authors (H.D. and H.A.) independently reviewed the titles and abstracts of the retrieved articles and then all selected articles by two authors were again screened based on the full text of manuscripts. Two authors (H.D. and H.A.) had discussed the disagreements in eligibility of studies, and if they did not reach a consensus, the third author (A.K.) made a decision.

Inclusion and exclusion criteria

All studies investigating any lymphocyte subset including T cell, B cell, NK cell (natural killer cell), CD4+ T helper cell and CD8+ T cytotoxic cells in the severe and non-severe patients infected with COVID-19 were included in

this study. Exclusion criteria were case reports, case series, reviews, editorials, comments, expert opinions, nonhuman studies, studies that did not report the immune signatures quantitatively, studies that did not clarify the severity status of patients, and studies on the pediatric population or patients with any medications/conditions that induced immunosuppression or changed immune cell counts.

Data extraction

Two authors independently extracted the following data from the included studies; authors' name, title, country of population, study design, date of publication, total sample size, the sample size of each group, subgroup definition, number and percentage of gender, average age, and its dispersion, average lymphocyte subsets count and their dispersions. Finally, two authors compared the extraction files of each other and solved the mismatches with a third author consulted in a case of conflict.

Quality assessment

The risk of bias assessment of the included studies was conducted with the Newcastle-Ottawa Quality Assessment Scale (NOQAS) and conducted by two authors, independently. In this part, no disagreement was left after two authors had reviewed and discussed their files.

Statistical analysis

All statistical analyses were conducted in STATA software (version 14.1). First, we extracted the mean count of lymphocyte subsets and their dispersion in non-severe and severe groups of COVID-19 individuals directly or indirectly by calculating the mean and standard deviation (SD) from median and interquartile range (IQR). Second, we computed standardized mean difference (SMD) between the two groups. Finally, we carried out a metaanalysis employing the random-effects model to pool the SMDs of each lymphocyte subset. Besides, we metaanalyzed each lymphocyte subset count to determine the pooled lymphocyte subsets count in non-severe and severe groups. We demonstrated the pooled SMDs and pooled lymphocyte subset counts in the forest plots. The Cochran Q test and I^2 index were applied to test the heterogeneity. P value<0.05 was considered to be significant in all statistical tests.

Results

Study selection and baseline characteristics

We retrieved a total of 5,877 documents through searching international databases. Besides, we found 15 eligible documents by manually searching the reference list of the incorporated articles. Finally, 39 articles (4-42) met the inclusion and exclusion criteria that were extracted for qualitative and quantitative analysis. Figure 1 shows the PRISMA diagram of the study. A total of 5087 participants with COVID-19 were included in our meta-analysis,




Figure 1. The PRISMA flowchart of the included studies.

including 3578 non-severe patients and 1509 severe patients. The sample sizes of the included studies ranged from 21 to 500, with 10 to 345 in the non-severe group and 5 to 155 in the severe group. The mean age of participants ranged from 42.3 years to 65.5 years. Table 1 shows the baseline characteristics of the study population.

Total T lymphocyte variation

The meta-analysis on 27 studies (4-6,8-10,15,16,18-20, 22,24-27,29-32,35-39,41,42) which assessed absolute T lymphocyte count in non-severe and severe cases showed that non-severe individuals had significantly higher total T cell count than severe patients (SMD = 1.01; 95% CI: 0.82, 1.20; $I^2 = 75.7\%$, *P* value < 0.001). Besides, we found that the average T cell count in non-severe patients was 878.88 cells/µL (95% CI: 818.08, 939.69) and in severe patients was 448.40 cells/µL (95% CI: 396.10, 500.71). The forest plots of pooled SMD for total T cell and pooled average T cell count in non-severe groups are shown in Figure 2.

CD4⁺ T cell variation

Thirty-nine studies (4-42) explored the count of CD4⁺ T cells in non-severe and severe patients. The pooled analysis showed that non-severe patients significantly had higher CD4⁺ T cell count than severe patients (SMD=1.07; 95% CI: 0.85, 1.28; I² = 85.4%, *P* value<0.001). In this instance, non-severe patients had a pooled CD4⁺ T cell count of 493.12 cells/µL (95% CI: 470.87, 515.38), and severe

patients had a pooled CD4⁺ T cell count of 268.96 cells/ μ L (95% CI: 239.56, 298.37). The forest plots of pooled SMD for CD4⁺ T cells and pooled average CD4⁺ T cell count in non-severe and severe groups are shown in Figure 3.

CD8⁺ T cell variation

Around 35 studies (4-10,12,13,15-34,37-42) explored the count of CD8⁺ T cells in non-severe and severe patients. The pooled SMD of CD8⁺ T cells between groups showed that non-severe patients significantly had higher CD8⁺ T cell count than severe patients (SMD = 1.07; 95% CI: 0.82, 1.32; $I^2 = 87.1\%$, *P* value < 0.001). In this instance, non-severe patients had a pooled CD8⁺ T cell count of 311.91 cells/µL (95% CI: 295.70, 328.12) and severe patients had a pooled CD8⁺ T cells/µL (95% CI: 140.05, 177.77). The forest plots of pooled SMD for CD8⁺ T cells and pooled average CD8⁺ T cell count in non-severe and severe groups are shown in Figure 4.

B cell variation

Twenty-two studies (4,6,9-11,13,15,16,18,19,22,24-26, 29-31,35,36,38,39,42) explored the count of B cells in non-severe and severe patients. The pooled SMD for B cells count was 0.72 with 95% CI of 0.45 to 0.98 ($I^2 = 79.7\%$, *P* value < 0.001). Thus, the absolute B cells count was significantly higher in non-severe cases than those in severe patients. Further analysis showed that the pooled average B cells count in non-severe patients was 177.09 cells/µL (95% CI:163.06, 191.11) while in those severe


Dehghanbanadaki H et al


Table 1. Baseline characteristics of included studies

Author, Year	Country	Study design	Sample size (n)	Subgroup definition	Male, n (%)	Age, mean (SD) (years)	Lymphocyte subsets
Chen et al (4), 2020	China	Retrospective cross-sectional	21	10 Moderate/ 11 severe	17 (81%)	55.9 (8)	T, NK, B, Th, Ts cells
Liu et al (5) 2020	China	Retrospective cross-sectional	110	49 Moderate/ 61 severe	60 (54.5%)	63.5 (13.8)	T, NK, Th, Ts cells
Xu et al (6) 2020	China	Retrospective cross-sectional	125	80 Mild/ 45 severe	69 (55%)	60.5 (15.1)	T, NK, B, Th, Ts cells
Yang et al (7) 2020	China	Retrospective cross-sectional	39	14 Moderate/ 25 severe	11 (29%)	57.6 (6.6)	Th, Ts cells
Chen et al (8) 2020	China	Cohort (historical/ retrospective)	500	345 Mild, moderate/155 severe	285 (57%)	65 (12.7)	T, Th, Ts cells
Zhang et al (9) 2020	China	Cohort (historical/ retrospective)	310	5Asymptomatic/ 293 mild/ 12 severe	NR	NR	T, NK, B, Th, Ts cells
Qin et al (10) 2020	China	Retrospective cross-sectional	44	17 Non-severe/ 27 severe	NR	57.1 (13.7)	T, NK, B, Th, Ts cells
Zheng et al (11) 2020	China	Cohort (historical/ retrospective)	68	55 Mild/ 13 severe	36 (53%)	47.1 (48.6)	B, Th cells
liu et al (12) 2020	China	Cohort (historical/retrospective)	76	46 Mild/30 severe	NR	NR	Th, Ts cells
Wan et al(13) 2020	China	Cohort (prospective)	123	102 Mild/ 21 severe	66 (54%)	46.1 (13.4)	NK, B, Th, Ts cells
Yang P et al (14) 2020	China	Cohort (historical/ retrospective)	133	65 Mild/ 68 severe	72 (54%)	50.8 (15.7)	Th cells
jiang et al (15) 2020	China	Case-Control	103	86 Mild, moderate/ 17 severe	58 (56%)	49.7 (10.5)	T, NK, B, Th, Ts cells
Liu et al (16) 2020	China	Retrospective cross-sectional	39	21 Mild, moderate/ 18 severe, critical	NR	51.7 (14.4)	T, NK, B, Th, Ts cells
Wei et al (17) 2020	China	Retrospective cross-sectional	167	137 Non-severe/ 30 severe	95 (57%)	42.3 (14.9)	Th, Ts cells
Sun et al (18) 2020	China	Retrospective cross-sectional	54	8 Mild/ 36 moderate/ 10 severe	31 (58%)	47.1 (41.9)	T, NK, B, Th, Ts cells
He et al (19) 2020	China	Retrospective cross-sectional	204	135 Non-severe/ 69 severe	79 (39%)	49 (16.2)	T, NK, B, Th, Ts cells
Feng et al (20) 2020	China	Retrospective cross-sectional	240	214 Moderate/ 26 severe	134 (56%)	51.5 (18.5)	T, Th, Ts cells
Ma J et al (21) 2020	China	Retrospective cross-sectional	37	17 Mild/ 20 severe, critical	20 (54%)	64 (7)	Th, Ts cells
Li S et al (22) 2020	China	Retrospective cross-sectional	69	43 Non-severe/ 26 severe	40 (58%)	47.5 (19.3)	T, NK, B, Th, Ts cells
Yang F et al (23) 2020	China	Retrospective cross-sectional	52	33 Mild/ 19 severe, critical	NR	NR	Th, Ts cells
Li X et al (24) 2020	China	Retrospective cross-sectional	215	159 Non-severe/ 56 severe	127 (59%)	44.5 (23.2)	T, NK, B, Th, Ts cells
Han M et al (25) 2020	China	Retrospective cross-sectional	154	122 Mild/ 32 severe	86 (56%)	42.5 (14.7)	T, NK, B, Th, Ts cells

Table 1. Continued

Author, Year	Country	Study design	Sample size (n)	Subgroup definition	Male, n (%)	Age, mean (SD) (years)	Lymphocyte subsets
Liu J et al (26) 2020	China	Retrospective cross-sectional	156	62 Moderate/ 94 severe	75 (48%)	65.5 (13)	T, NK, B, Th, Ts cells
Xiong et al (27) 2020	China	Retrospective cross-sectional	116	61 Non-severe/ 55 severe	81 (70%)	58 (18.5)	T, Th, Ts cells
Kalpakci et al (28) 2020	Turkey	Retrospective cross-sectional	40	20 Non-severe/ 20 severe	20 (50%)	63.6 (14)	Th, Ts cells
Zou et al (29) 2020	China	Retrospective cross-sectional	121	69 Non-severe/ 52 severe	66 (55%)	64.4 (12.4)	T, NK, B, Th, Ts cells
He et al (30) 2020	China	Retrospective cross-sectional	53	32 Mild/ 21 severe	NR	NR	T, NK, B, Th, Ts cells
Wu et al (31) 2020	China	Retrospective cross-sectional	60	31 Mild/ 29 severe	37 (62%)	57.8 (17.2)	T, NK, B, Th, Ts cells
Wu et al (32) 2020	China	Cohort (historical/retrospective)	201	117 Not ARDS/ 84 ARDS	128 (64%)	52.2 (11.9)	T, Th, Ts cells
Chen et al (33) 2020	China	Retrospective cross-sectional	123	13Asymptomatic/ 16mild/ 89 moderate/ 5 severe	65 (53%)	45.3 (17)	Th, Ts cells
Zhou et al (34) 2020	China	Cohort (prospective)	83	66 Non-severe/ 17 severe	42 (51%)	46.7 (14)	Th, Ts cells
Jin et al (35) 2020	China	Cohort (prospective)	146	106 Non-severe/ 40 severe	77 (53%)	46.7 (53.5)	T, NK, B, Th, cells
Yi et al (36) 2020	China	Retrospective cross-sectional	100	51 Non-severe/ 49 severe	63 (63%)	54.1 (15)	T, NK, B, Th, cells
Xie et al (37) 2020	China	Retrospective cross-sectional	373	322 Non-severe/ 51 severe	197 (53%)	NR	T, Th, Ts cells
Liu et al (38) 2020	China	Retrospective cross-sectional	50	10Mild/ 32 moderate/ 8 severe	28 (55%)	NR	T, NK, B, Th, Ts cells
d'Alessandro et al (39) 2020	Italy	Retrospective cross-sectional	54	40 Non-severe/ 14 severe	33 (61%)	64.8 (12.2)	T, NK, B, Th, Ts cells
Wang et al (40) 2020	China	Retrospective cross-sectional	130	104 Not ARDS/ 26 ARDS	61 (47%)	47.1 (18.9)	Th, Ts cells
Huang et al (41) 2020	China	Cohort (prospective)	89	70 Moderate/ 19 severe	NR	NR	T, Th, Ts cells
Cai et al (42) 2020	China	Cohort (prospective)	41	19 Non-severe/ 22 severe	21 (51%)	59.6 (13.4)	T, NK, B, Th, Ts cells








Figure 3. The forest plot of pooled effect on the standardized mean difference (SMD) of CD4+T cell between non-severe and severe groups (a) and average CD4+T cell count in non-severe and severe groups (b).




Figure 4. The forest plot of pooled effect on the standardized mean difference (SMD) of CD8+ T cell between non-severe and severe groups (a) and average CD8+ T cell count in non-severe and severe groups (b).

patients was 110.37 cells/ μ L (95% CI:100.38, 120.36). The forest plots of pooled SMD for B cells and the pooled average B cell count in non-severe and severe groups are shown in Figure 5.

Natural killer cell variation

Twenty-two studies (4-6,9,10,13,15,16,18,19,22,24-26,29-31,35,36,38,39,42) explored the count of NK cells in nonsevere and severe patients. The pooled SMD analysis showed that non-severe patients had higher NK cells count than severe COVID-19 patients (SMD = 0.65; 95% CI: 0.47, 0.84; I² = 63.1%, *P* value < 0.001). In this instance, non-severe patients had pooled average NK cells count of 155.02 cells/µL (95% CI:143.46, 166.58) while severe patients had pooled average NK cells count of 103.09 cells/ µL (95% CI:90.09, 116.10; Figure 6).

Discussion

Nowadays, researchers are extensively searching to find more robust predicting factors in COVID-19 (43). Several studies have investigated the profiles of immune cells and mediators during different phases of COVID-19 in various populations that resulted in different outcomes, possibly due to the different ethnicity, the technique of assessment, and clinical and paraclinical characteristics of the patients (2,44). Therefore, we conducted this systematic review and meta-analysis to explore the association among lymphocyte variation and disease severity because identification of lymphocyte variation may provide more accurate insight for adopting therapeutic approaches in patients with different clinical stages.

A bulk of evidence showed that although T cell counts were normal or even slightly higher in patients with mild symptoms, total T lymphocytes, CD4+, CD8+ T lymphocytes, B lymphocytes and natural killer cells were usually below the normal range in COVID-19 patients resulting in lymphopenia that was associated with disease severity and mortality in COVID-19 individuals (45,46). In the present systematic review and meta-analysis, we demonstrate that non-severe patients had a significantly higher total T cell count than severe patients. Correspondingly, the pooled analysis showed that non-severe patients had significantly higher CD4+ and CD8⁺ T cell, natural killer cell and B cell counts than severe patients. Although these findings are consistent with previous studies (45,46), inflammatory cytokine levels were not evaluated to correlate disease severity and cytokine storm, which might serve as a signature of severe COVID-19. A systematic meta-analysis of immune signatures in patients with COVID-19 showed that CD3⁺, CD4+, CD8+ T cells, CD4+CD25+CD127-Treg cells, CD19+ B cells and CD16⁺CD56⁺ NK cells were significantly decreased in severe COVID-19 patients than in non-severe ones (47). In addition, many other studies established that the total counts of lymphocyte subsets, both B and

T cells, were significantly lower in both individuals with severe and non-severe COVID-19 (48,49). Several studies showed that lymphocytes were diminished in COVID-19 patients, whereas no significant difference was observed in NK cell counts (50,51). Contradictory results on NK cells necessitate further studies to shed more light on this issue. Huang et al (52), in a recent meta-analysis, demonstrated that lymphopenia correlated with poor outcomes and higher mortality in COVID-19 patients; therefore, inducing lymphocyte proliferation to increase or apoptosis to decrease (IL-7 and PD1/PD-L1 inhibitors) lymphocyte counts may help retrieve lymphocyte population in patients with severe COVID-19 for reducing COVID-19 mortality.


Most hospitalized patients have shown suboptimal, excessive, or inappropriate T cell responses in association with severe disease. Consequently, several discrete patterns of T cell responses may be found in different patients, indicating each patient is faced with different clinical outcomes. Thereby customizing therapeutic approaches may be beneficial to decrease the mortality of severe to critically ill cases with COVID-19 (53). On the other hand, a decrease of lymphocytes can be used as the prognostic factor for COVID-19 patients in the clinical setting. The lymphocytic cells cut point in our study can guide further studies to determine which patients should be warned to be a severe case of COVID-19 and cared cautiously. As antivirals, immunoglobulin, and glucocorticoids treatments have not shown a significant improvement in the survival of COVID-19 severe patients (54), immunotherapeutic strategies can be a promising treatment option for enhancing the lymphocytes. Novel therapeutic options as NK cell-based therapy, mesenchymal stem cell (MSC)-based therapy, and regulatory T cellbased therapy have been lately introduced, and trials are going on to assess these treatment strategies(55).


COVID-19 affects lymphocytes through direct and/ or indirect mechanisms. The direct mechanism may be related to SARS-CoV-2 cytotoxicity, in which the virus actively replicates within infected lymphocytes (56,57). The indirect mechanism is attributed to the large production of inflammatory cytokines that potentially induce lymphocyte apoptosis (57). In addition, constitutive stimulation by a virus may cause T cell exhaustion in which T cells diminish or lose their capacity of cytokine production and effector functions (58). Similarly, SARS-CoV2-related exhaustion in lymphocytes may be due to some inhibitory cytokines, e.g., IL-10, that is significantly increased in COVID-19 patients (59). However, the exact mechanism(s) of lymphocyte reduction in individuals with severe COVID-19 remain to be completely clarified.

The present study had limitations that were common in all meta-analysis studies. We did not determine the impact of age, gender, cytokine levels, inflammatory mediators, predisposing comorbidities, effective anti-cytokine therapy

First			%
author	Month	SMD of B cell (95% Cl)	Weigh
Chen G	March	-0.40 (-1.26, 0.47)	3.85
Qin C	March	◆ 0.19 (-0.42, 0.80)	4.86
Zheng M	March	• 0.21 (-0.39, 0.82)	4.88
Wan S	March	• 3.32 (2.70, 3.95)	4.78
_iu Z	March	• 0.33 (-0.31, 0.96)	4.76
Ku B	April	 1.11 (0.72, 1.51) 	5.73
Sun Y	April —	2.71 (-66.46, 71.89)	0.00
Sun Y	April	0.27 (-51.86, 52.40)	0.00
He R	April	♦ 1.21 (0.90, 1.53)	6.00
Zhang X	May —	0.73 (-111.27, 112.73)	0.00
Zhang X	May -	0.31 (-61.66, 62.28)	0.00
iang M	May	♦ 0.57 (0.05, 1.10)	5.20
lS	June	 1.13 (0.61, 1.66) 	5.21
Nu Y	July	• 0.40 (-0.11, 0.91)	5.26
Han M	August	• 0.47 (0.08, 0.86)	5.72
Zou L	August	♦ 0.81 (0.44, 1.19)	5.79
He B	August	◆ 0.40 (-0.16, 0.95)	5.08
	-		
_iu F	August	1.20 (-97.15, 99.55)	0.00
Liu F	August	• 0.45 (-81.51, 82.41)	0.00
_i X	September	♦ 0.67 (0.36, 0.99)	6.00
_iu J	October	♦ 0.77 (0.43, 1.10)	5.93
d'Alessandro M	October	◆ 0.30 (-0.31, 0.91)	4.85
Jin XH	November	• 0.04 (-0.32, 0.41)	5.82
Cai L	November	 ♦ 1.27 (0.60, 1.95) 	4.59
Yi P	December	• 0.62 (0.22, 1.02)	5.69
Jverall (I-square	d = 79.7%, p = 0.000)	0.72 (0.45, 0.98)	100.0
NOTE: Weights a	re from random effects analysis		
	-100	I I 0 100	
	-100	0 100	
First		Mean of B cell,	%
author	Month	cells/µL (95% CI)	Weight
Non-severe			
Chen G	March	▲ 117.27 (103.17, 131.36)	5.18
Chen G Qin C	March	196.10 (127.22, 264.98)	2.36
Chen G Qin C Zheng M	March March	196.10 (127.22, 264.98) 158.40 (101.63, 215.17)	2.36 2.88
Chen G Qin C	March	196.10 (127.22, 264.98)	2.36
Chen G Qin C Zheng M Wan S Liu Z Xu B	March March March March April	196 10 (127 22, 264 98) 155 40 (101 83, 216 77) 166 00 (163 68, 168 32) 183 33 (108 25, 258 42) 226 67 (200 37, 252 96)	2.36 2.88 5.46 2.13 4.59
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y	March March March April April	1961 10 (127 22, 264 98) 156 40 (101 63, 215 17) 166 000 (163 88, 168 32) 183 33 (106 25, 258 42) 226 67 (200 37, 252 96) 330 71 (275 80, 384 52)	2.36 2.88 5.46 2.13 4.59 3.03
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y	March March March Arril April April April	196 10 (127 22, 264 98) 155 40 (101 63, 215 17) 166 00 (163 96, 163 22) 183 33 (108 25, 258 42) 201 183 33 (108 25, 258 42) 183 30 71 (276 80, 384 52) 188 90 (119 72, 176 80)	2.36 2.88 5.46 2.13 4.59 3.03 4.42
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R	March March March April April April April April	1961 10 (127 22, 264 98) 156 40 (101 63, 215 17) 166 000 (163 88, 168 32) 183 33 (106 25, 258 42) 226 67 (200 37, 252 96) 330 71 (275 80, 384 52)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y	March March April April April April April May May	1961 10 (127 22, 224 98) 158.40 (101.63, 215.17) 166.00 (183.88, 168.32) 183.33 (108.25, 258.42) 22.667 (200.37, 252.96) 330.71 (276.90, 384.52) 148.90 (119.72, 175.06) 199.00 (182.88, 215.12)	2.36 2.88 5.46 2.13 4.59 3.03 4.42
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Jiang M	March March April April April April May May May	196, 10 (127 22, 284, 98) 158, 40 (101, 83, 215, 17) 166, 00 (163, 84, 164, 32) 183, 33 (102, 55, 254, 42) 288, 67 (200, 37, 252, 96) 30, 071 (27, 60, 90, 344, 52) 30, 071 (27, 60, 90, 344, 52) 199, 00 (112, 22, 176, 20) 199, 00 (112, 28, 215, 12) 27, 73 (214, 35, 340, 31) 222, 33 (113, 74, 146, 53)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang X Liu S	March March April April April April May May May June	196 10 (127 22, 264 98) 155 40 (101 83, 216 77) 166 00 (163 68, 168 32) 183 33 (108 25, 258 42) 183 33 (108 25, 258 42) 303 71 (276 80, 384 52) 184 80 (119, 72, 702 89) 199 00 (182 88, 215 12) 277 33 (214 35, 340 31) 222 33 (219 70, 244 97) 130 33 (113 74, 146 93) 177, 100 (149 30, 192 70)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang M Li S Wu Y	March March April April April April May May May June July	1961 10 (127 22, 224 98) 158, 40 (101, 63, 215 17) 166, 000 (163, 84, 168, 32) 183, 33 (108, 25, 258, 42) 218, 33 (108, 25, 258, 42) 218, 33 (108, 25, 258, 42) 218, 33 (101, 82, 528, 42) 219, 30 (119, 72, 178, 68) 199, 00 (118, 28, 218, 12) 277, 33 (214, 35, 340, 31) 277, 33 (214, 35, 340, 31) 277, 33 (214, 35, 340, 31) 277, 33 (113, 74, 146, 93) 171, 00 (149, 30, 182, 70) 125, 67 (128, 11, 168, 22)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Li S Wu Y Han M	March March April April April April May May May June June June	196 10 (127 22, 264 98) 156 40 (101 83, 215 17) 166 00 (163 36, 168 32) 183 33 (108 25, 258 42) 183 33 (108 25, 258 42) 183 30 71 (278 90, 384 52) 189 00 (192 28, 215 12) 199 00 (182 88, 215 12) 199 00 (192 88, 215 12) 199 00 (193 88, 115 12) 199 00 (198 88, 115 12) 199 00 (198 88, 115 12) 199 00 (198 88, 11	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21 5.09
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang M Li S Wu Y	March March April April April April May May May June July	1961 10 (127 22, 224 98) 158, 40 (101, 63, 215 17) 166, 000 (163, 84, 168, 32) 183, 33 (108, 25, 258, 42) 218, 33 (108, 25, 258, 42) 218, 33 (108, 25, 258, 42) 218, 33 (101, 82, 528, 42) 219, 30 (119, 72, 178, 68) 199, 00 (118, 28, 218, 12) 277, 33 (214, 35, 340, 31) 277, 33 (214, 35, 340, 31) 277, 33 (214, 35, 340, 31) 277, 33 (113, 74, 146, 93) 171, 00 (149, 30, 182, 70) 125, 67 (128, 11, 168, 22)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L He B Liu F	March March April April April April May May May July August August August August	196 10 (127 22, 264 98) 155 40 (101 83, 215 17) 166 00 (163 68, 168 32) 183 33 (108 25, 258 42) 276 50 (203 7, 222 96) 300 71 (276 50, 384 52) 184 80 (119, 72, 176 80) 199 00 (182 88, 215 12) 277 33 (214 35, 340 31) 277 33 (214 35, 340 31) 277 33 (214 35, 340 31) 277 33 (214 35, 340 31) 150 00 (113 74, 148 93) 177, 100 (143 30, 112 70) 125 67 (208 1, 158 52) 144 33 (127 90, 160 76) 157 00 (141 62, 172 38) 150 00 (117, 76 47)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L He B Liu F	March March April April April April May May Juny Juny Juny August August August August August	196, 10 (127 22, 284, 98) 156, 40 (101 43, 215, 17) 166, 00 (163 46, 163 32) 183, 33 (108 25, 253 42) 226, 67 (203, 77, 282, 96) 330, 71 (276 30, 384, 52) 183, 30 (118, 27, 176, 06) 199, 00 (112, 28, 151, 12) 277, 33 (143, 53, 403, 11) 222, 33 (113, 74, 146, 93) 177, 100 (149, 30, 112, 77) 182, 433, 112, 74, 146, 93) 177, 100 (149, 30, 112, 73) 177, 100 (141, 26, 172, 38) 177, 100 (111, 76, 1182, 24) 244, 57 (112, 27, 376, 47) 125, 457 (140, 78, 210, 16)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Zhang X Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L He B Liu F Liu F Liu F Liu X	March March April April April April April May May May June July August August August August August August August Saptember	196, 10 (172 22, 264, 90) 156, 40 (101 83, 215, 17) 156, 40 (101 82, 17, 262, 96) 30, 30, 71 (276 80, 384, 52) 168, 50 (119, 72, 17, 26) 199, 00 (182, 88, 215, 12) 177, 30 (214, 35, 30, 31) 273, 32 (214, 57, 30, 31) 273, 32 (214, 57, 30, 31) 273, 32 (214, 57, 30, 31) 175, 700 (141, 82, 172, 38) 157, 700 (111, 82, 17) 152, 507 (124, 188, 24) 157, 700 (111, 82, 17) 152, 507 (114, 78, 124, 19) 157, 700 (111, 82, 17) 152, 507 (112, 78, 182, 44) 254, 57 (132, 67, 78, 47) 152, 800 (111, 78, 134, 97) 152, 800 (111, 78, 134, 97)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.00 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10 5.26
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Ilang M Li S Wu Y Han M Zou L He B Liu F Liu F Liu F Liu J	March March April April April April April May May June July August Augus	196, 10 (127 22, 284, 98) 158, 40 (101, 83, 215, 17) 166, 00 (163, 68, 163, 22) 183, 33 (108, 55, 258, 42) 228, 67 (220, 37, 282, 96) 330, 71 (274, 80, 384, 52) 330, 71 (274, 80, 384, 52) 330, 71 (274, 80, 384, 52) 199, 00 (112, 28, 121, 12) 177, 100 (143, 30, 192, 70) 125, 67 (284, 11, 168, 52) 144, 33 (1127, 90, 168, 76) 155, 00 (111, 76, 188, 52) 144, 33 (127, 90, 167, 66) 157, 00 (111, 22, 172, 38) 150, 00 (111, 76, 188, 24) 126, 477 (140, 78, 210, 16) 128, 200 (114, 52, 101, 60) 128, 200 (147, 55, 188, 55) 144, 320 (147, 55, 188, 55)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.09 5.13 3.89 1.07 4.10 5.26 4.84
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Zhang X Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L He B Liu F Liu F Liu F Liu X	March March April April April April April May May May June July August August August August August August August Saptember	196, 10 (172 22, 264, 90) 156, 40 (101 83, 215, 17) 156, 40 (101 82, 17, 262, 96) 30, 30, 71 (276 80, 384, 52) 168, 50 (119, 72, 17, 26) 199, 00 (182, 88, 215, 12) 177, 30 (214, 35, 30, 31) 273, 32 (214, 57, 30, 31) 273, 32 (214, 57, 30, 31) 273, 32 (214, 57, 30, 31) 175, 700 (141, 82, 172, 38) 157, 700 (111, 82, 17) 152, 507 (124, 188, 24) 157, 700 (111, 82, 17) 152, 507 (114, 78, 124, 19) 157, 700 (111, 82, 17) 152, 507 (112, 78, 182, 44) 254, 57 (132, 67, 78, 47) 152, 800 (111, 78, 134, 97) 152, 800 (111, 78, 134, 97)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.00 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10 5.26
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L Han M Zou L He B Liu F Liu F Liu F Liu J d'Alessandro M	March March April April April April April May May May June July August August August August August August August August August August October October	196, 10 (172 22, 264, 98) 156, 40 (101 83, 215 17) 156, 40 (101 83, 215 17) 158, 40 (101 82, 226 18) 303, 71 (278 90, 384 52) 183, 303, 71 (278 90, 384 52) 199, 90 (182, 88, 215 12) 199, 90 (182, 88, 216 12) 199, 90 (182, 89, 113 12) 199, 90 (182, 89, 113 12) 199, 90 (118, 20, 113 44, 118, 24) 190, 90 (111 62, 113 27) 198, 82 (113, 527) 198, 82 (115, 712, 105, 89) 191, 105 (112, 72, 105, 89) 191, 105 (2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.09 5.13 3.89 1.07 4.10 5.26 4.84 4.21 5.09 5.13 3.89 1.07 4.10
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang X Zhang X Zhang X Li S Ular G Lu F Liu F Liu F Liu F Liu F Liu Z Jin XH Cai L Yi P	March March Arril April April April April April May May May May July August Aug	196, 10 (127 22, 284, 98) 196, 10 (127 22, 284, 98) 196, 20 (127 22, 284, 98) 196, 20 (127 22, 284, 98) 196, 20 (127 22, 284, 98) 288, 67 (200, 27, 252, 96) 298, 67 (200, 27, 252, 96) 298, 67 (200, 27, 252, 96) 298, 67 (200, 27, 252, 96) 299, 00 (128, 82, 17, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10 5.26 4.89 3.29 2.35 3.14 4.67
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang X Zhang X Zhang X Li S Ular G Lu F Liu F Liu F Liu F Liu F Liu Z Jin XH Cai L Yi P	March March March April April April April April May May May June July August August August August August August August September October November	196, 10 (127 22, 264, 98) 156, 40 (101 83, 215, 17) 166, 00 (163 36, 168 32) 183 33 (108 25, 258 42) 183 33 (108 25, 258 42) 193 30 71 (276 80, 384 52) 184 80 (1187, 27, 176, 80) 199 00 (112 28, 125, 12) 199 00 (128, 28, 151, 12) 199 00 (128, 28, 151, 12) 171, 00 (149, 30, 122, 70) 125 67 (120, 37, 146, 89) 177, 100 (149, 30, 122, 70) 125 67 (120, 37, 146, 89) 177, 100 (114, 82, 70, 24) 167, 700 (114, 82, 70, 24) 168, 200 (117, 55, 188, 24) 252, 200 (122, 90, 32), 100 252, 200 (122, 90, 32), 100 254, 200 (122, 90, 32), 100 254, 200 (112, 70, 126) 254, 200 (12, 70, 126) 254, 2	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 4.84 4.21 5.08 4.84 4.21 5.08 5.13 3.89 1.07 4.10 5.26 4.89 3.29 2.35 3.14
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y Han R Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L He B Liu F Liu F Liu F Liu F Liu F Liu F Liu F Cai L Y Q Subtotal (I-squared Severe	March March March April April April May May May July July August August August September October October November November December E August	196, 10 (172 22, 28.49) 158, 40 (101 83, 215, 17) 166, 00 (163 66, 163 32) 183, 33 (108, 25, 258, 42) 283, 33 (108, 25, 258, 42) 293, 30 (71 (276 80, 384, 52) 184, 30 (118, 72, 176, 80) 199, 00 (112, 28, 151, 12) 273, 32 (14, 35, 340, 31) 222, 33 (181, 74, 146, 93) 171, 100 (149, 30, 182, 70) 144, 33 (127, 90, 160, 76) 175, 700 (114, 82, 717, 24) 164, 33 (127, 90, 160, 76) 177, 700 (114, 82, 717, 24) 164, 27, 714, 40, 78, 12) 175, 700 (114, 12, 717, 24) 175, 700 (114, 12, 717, 24) 164, 200 (117, 72, 168, 24) 175, 700 (114, 22, 717, 34) 164, 27, 714, 74, 72, 12, 16) 175, 700 (112, 20, 178, 48) 164, 77, 700 (132, 20, 161, 80) 177, 09 (183, 06, 191, 11) 177, 09 (183, 06, 191, 11)	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.10 2.60 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10 5.26 4.89 1.07 5.26 4.89 1.02 5.26 4.89 1.02 5.26 4.89 5.13 3.29 2.35 3.14 4.67 100.00
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y Han M Zhang X Zhang X Zhang X Zhang X Zhang X Liag Wu Y Han M Li S Wu Y Han M Li S U S U Li Liu F Liu F Liu F Liu F Cai L Yi P Subtotal (I-squared Severe Chen G	March March April April April April April April May May May May June July August Augus	196, 10 (172 22, 264, 90) 158, 40 (101 63, 25, 258, 42) 153, 33 (104 25, 258, 42) 153, 33 (104 25, 258, 42) 153, 30 71 (278, 90, 384, 52) 164, 90 (115, 27, 170, 90) 199, 00 (162, 88, 215, 12) 277, 33 (214, 53, 30, 31) 222, 33 (219, 70, 244, 97) 130, 33 (113, 74, 148, 93) 171, 100 (143, 90, 192, 70) 125, 67 (202, 17, 26, 90) 125, 67 (202, 17, 26, 90) 125, 67 (202, 17, 26, 90) 199, 00 (112, 28, 151, 12) 277, 33 (214, 53, 430, 31) 222, 33 (219, 70, 244, 97) 130, 33 (113, 74, 148, 93) 177, 100 (143, 90, 192, 70) 125, 67 (124, 71, 76, 40) 157, 00 (114, 82, 172, 38) 157, 00 (114, 82, 172, 38) 158, 00 (114, 82, 172, 38) 159, 00 (114, 82, 172, 38) 159, 00 (114, 82, 172, 38) 159, 00 (114, 82, 173, 126, 98) 157, 00 (112, 82, 18, 80, 98) 157, 00 (132, 20, 181, 80) 157, 00 (132, 20, 181, 80) 157, 00 (132, 20, 181, 80) 157, 00 (152, 20, 181,	2.36 2.88 5.46 2.13 4.59 3.03 4.42 5.00 5.24 5.08 4.84 4.21 5.09 5.13 3.89 1.07 4.10 5.26 4.89 3.29 2.35 3.14 4.67 100.00 0.88
Chen G Qin C Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y He R Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L Wu Y Han M Zou L U He B Liu F Liu F Liu F Liu F Liu F Liu F Subtotal (I-squared Severe Chen G Qin C	March March March April April April May May May May July August August August September October October October October October October October October Movember November March March	196, 10 (127 22, 284, 98) 196, 10 (127 22, 284, 98) 196, 20 (17 22, 284, 98) 193, 33 (108, 26, 158, 32) 193, 33 (108, 26, 158, 32) 193, 30 (71 (274, 80, 384, 52) 183, 33 (108, 27, 176, 08) 199, 00 (112, 28, 125, 12) 199, 00 (112, 28, 125, 12) 177, 30 (143, 35, 40, 31) 222, 33 (219, 70, 244, 97) 133, 33 (113, 74, 146, 93) 177, 100 (143, 30, 192, 70) 125, 67 (92, 81, 158, 52) 177, 100 (114, 22, 172, 38) 167, 70 (142, 172, 38) 164, 77 (142, 78, 210, 16) 128, 20 (112, 75, 188, 24) 126, 20 (112, 70, 188, 24) 127, 73 (143, 53, 120, 16) 128, 20 (112, 75, 188, 24) 126, 20 (112, 70, 188, 24) 127, 73 (136, 51, 280, 06) 157, 00 (112, 70, 118, 26) 164, 70 (163, 61, 381, 97) 166, 70 (152, 70, 221, 16) 166, 70 (152, 70, 221, 16) 169, 00 (115, 58, 522, 15)	2.38 2.88 2.46 2.13 3.03 4.42 3.03 4.42 2.50 5.24 5.08 1.07 4.10 5.08 3.89 1.07 4.10 5.26 3.89 1.07 4.10 5.28 3.34 4.467 100.00
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Li S Wu Y Han M Li S U S Li Li F Liu F Liu F Liu F Cai L X Subtotal (I-squared Severe Chen G Gin C Zheng M	March March April April April April April June June July August August August August Cotober October November December Is e26%, p = 0.000)	196, 10 (172 22, 264, 98) 196, 10 (172 22, 264, 98) 198, 20 (115 32, 215 17) 198, 20 (115 32, 215 17) 198, 20 (115 32, 215 17) 198, 20 (115 32, 215 12) 199, 20 (118 25, 258 42) 213, 33 (116 25, 258 42) 213, 33 (116 25, 258 42) 213, 33 (113 27, 170, 89) 199, 20 (118 28, 215, 12) 217, 10 (148 28, 215, 12) 217, 10 (148 28, 215, 12) 217, 10 (148 28, 215, 12) 177, 10 (148 29, 12) 182, 20 (116 29, 123, 161, 82) 182, 20 (116 29, 123, 161, 82) 177, 20 (113 28, 128, 96) 157, 20 (132 20, 161, 80) 177, 20 (132 20, 161, 90) 174, 20 (132 20, 20, 20) 174, 20 (132 20	2.38 2.88 2.46 2.13 4.59 3.03 4.42 5.26 4.84 4.21 5.26 4.84 4.21 1.07 4.10 5.28 4.84 4.21 1.07 4.10 5.28 3.89 3.29 3.235 3.14 4.67 100.00 0.88 2.250 1.01
Chen G Qin C Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y He R Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L Wu Y Han M Zou L U He B Liu F Liu F Liu F Liu F Liu F Liu F Subtotal (I-squared Severe Chen G Qin C	March March March April April April May May May May July August August August September October October October October October October October October Movember November March March	196, 10 (127 22, 284, 98) 196, 10 (127 22, 284, 98) 196, 20 (17 22, 284, 98) 193, 33 (108, 26, 158, 32) 193, 33 (108, 26, 158, 32) 193, 30 (71 (274, 80, 384, 52) 183, 33 (108, 27, 176, 08) 199, 00 (112, 28, 125, 12) 199, 00 (112, 28, 125, 12) 177, 30 (143, 35, 40, 31) 222, 33 (219, 70, 244, 97) 133, 33 (113, 74, 146, 93) 177, 100 (143, 30, 192, 70) 125, 67 (92, 81, 158, 52) 177, 100 (114, 22, 172, 38) 167, 70 (142, 172, 38) 164, 77 (142, 78, 210, 16) 128, 20 (112, 75, 188, 24) 126, 20 (112, 70, 188, 24) 127, 73 (143, 53, 120, 16) 128, 20 (112, 75, 188, 24) 126, 20 (112, 70, 188, 24) 127, 73 (136, 51, 280, 06) 157, 00 (112, 70, 118, 26) 164, 70 (163, 61, 381, 97) 166, 70 (152, 70, 221, 16) 166, 70 (152, 70, 221, 16) 169, 00 (115, 58, 522, 15)	2.38 2.88 2.46 2.13 3.03 4.42 3.03 4.42 2.50 5.24 5.08 1.07 4.10 5.08 3.89 1.07 4.10 5.26 3.89 1.07 4.10 5.28 3.34 4.467 100.00
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y He R Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U F Liu F Liu F Liu F Liu F Liu T Liu X Liu Z Xi Alessandro M Jin XH Cai L X Subtotal (I-squared Chen G Chen G Zheng M Wan S Liu Z Xu B	March March March April April April April April May May May June July August August August August August August August August August Cotober October October October October October November December I = 92.6%, p = 0.000) March	196, 10 (172, 22, 28, 98) 196, 10 (172, 22, 28, 98) 196, 20 (172, 22, 28, 98) 198, 33 (196, 25, 258, 42) 228, 67 (200, 37, 252, 96) 303, 07 (127, 80, 384, 52) 199, 30 (112, 28, 17, 17, 20, 99) 199, 00 (112, 28, 17, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12	2.36 2.48 2.48 5.46 2.13 3.03 4.42 5.00 2.80 0.82 4.84 4.21 5.04 4.21 5.04 4.21 5.04 4.21 5.04 4.21 5.04 4.21 5.04 5.24 4.21 5.04 5.24 5.24 5.24 5.24 5.24 5.24 5.24 5.2
Chen G Qin C Qin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U He B Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu S Subotal (I-squared Cai L Yi P Subotal (I-squared Chen G Qin C Zheng M Wan S Liu Z Zhang M Wan S Liu Z Zhang M Subotal (I-squared Chen G Qin C Zheng M	March March March April August August August August August Colober October October November December December March March March March March April	196, 10 (172, 22, 24, 98) 196, 10 (172, 22, 24, 98) 196, 20 (172, 22, 24, 98) 193, 33 (108, 26, 158, 22) 193, 33 (108, 26, 158, 22) 193, 33 (108, 26, 158, 22) 193, 33 (107, 27, 160, 984, 22) 194, 300, (117, 27, 170, 08) 199, 00 (128, 28, 151, 12) 273, 214, 35, 340, 31) 222, 33 (219, 70, 244, 97) 135, 67 (20, 37, 32, 24, 97) 155, 67 (20, 37, 32) 155, 70 (114, 22, 77, 38) 164, 67 (104, 78, 120, 16) 177, 70 (163, 38, 20) 177, 70 (163, 36, 191, 11) 177, 70 (163, 66, 191, 11) 166, 70 (65, 80, 287, 60) 175, 30 (115, 35, 10) 175, 30 (115, 35, 10) 175, 30 (115, 35, 10)	2.36 2.88 5.46 2.13 3.03 4.459 5.00 2.60 4.42 5.01 2.60 5.24 4.51 2.524 4.51 3.389 4.84 4.21 5.09 5.13 3.89 3.29 2.35 3.14 4.00 0.88 2.35 3.146 7.00 0.88 3.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U He B Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu T Liu S Col Liu F Chan G Gin C Zheng M Wan S Liu Z Xu B Sun Y He R	March March March April April April April April May May May July August August August August August August August August August August August August August Discomber October October October October October November December I = 92.6%, p = 0.000) March March March March March March April April April April April April April April April April August	196, 10 (172, 22, 28, 49) 196, 10 (172, 22, 28, 49) 198, 33 (109, 25, 258, 42) 198, 30 (119, 27, 175, 60) 199, 00 (128, 82, 151, 12) 177, 33 (21, 43, 54, 03, 31) 222, 33 (21, 70, 244, 97) 133, 33 (113, 74, 146, 93) 177, 100 (149, 30, 122, 70) 188, 26) 199, 00 (128, 21, 12) 175, 47 (140, 78, 210, 16) 199, 00 (128, 21, 12) 175, 47 (140, 78, 210, 16) 199, 00 (128, 21, 12) 199, 00 (128, 21, 12) 199, 00 (128, 21, 12) 199, 00 (128, 21, 12) 199, 00 (118, 22) 100 (111, 76, 188, 29) 114, 60 (21, 30, 207, 20) 125, 30 (119, 55, 10) 199, 00 (163, 55, 10) 199, 00 (163, 55, 10) 199, 00 (128, 00, 16), 10) 177, 09 (163, 06, 191, 11) 199, 00 (128, 00, 16), 10) 177, 09 (163, 06, 191, 11) 199, 00 (128, 00, 16), 10) 177, 09 (163, 06, 191, 11) 199, 00 (128, 00, 16), 10) 177, 09 (163, 06, 191, 11) 199, 00 (128, 00, 16), 10) 172, 00 (163, 00, 16), 10) 173, 00 (163, 00, 16), 10) 174, 00 (163, 163, 10) 174, 00	2.36 5.46 2.13 3.03 5.45 5.45 5.44 4.45 5.00 2.60 5.24 5.24 4.21 5.00 2.60 5.24 4.20 5.24 4.21 3.89 7.41 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 5.24 5.24 5.24 5.24 5.24 5.24 5.24
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L He B Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Subtotal (I-squared Severe Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Sun Y He R Sub Y Sun Y He R Sun Y He R Sub Y Sun Y He R Sub Sun Y He R Sub Sub Sub Sub Sub Sub Sub Sub Sub Sub	March March March April April April April May May May May May June July August August August Soptember October October Docember Docember Docember March	196, 10 (127 22, 264, 98) 196, 10 (127 22, 264, 98) 196, 20 (127 22, 264, 98) 193, 33 (108, 26, 153, 22, 28) 193, 33 (108, 26, 153, 22, 28) 330, 71 (278, 30, 384, 52) 194, 30 (118, 72, 177, 80) 199, 00 (128, 28, 151, 12) 273, 32 (14, 35, 40, 31) 222, 33 (113, 74, 146, 52) 171, 00 (149, 30, 118, 27) 172, 00 (117, 16, 116, 52) 174, 104, 29, 121, 104 194, 20 (117, 27, 168, 24) 194, 20 (112, 27, 374, 47) 194, 20 (118, 28, 121, 104) 194, 20 (112, 27, 121, 104) 194, 20 (112, 28, 118, 24) 194, 20 (112, 28, 121, 104) 194, 20 (113, 28, 222, 16) 1144, 20 (112, 30, 207, 30) 1125, 30 (115, 56, 108, 114, 104) 1123, 30 (112, 56, 108, 114) 1123, 30 (112, 56, 108, 114) 1123, 30 (112, 56, 108, 114) 1133, 31 (112, 76, 268, 81) 1143, 31 (112, 76, 268, 81) 1153, 30 (112, 56, 163, 104) 1153, 30 (112, 56, 163, 104) 1154, 30 (112, 56, 164, 104) 1154, 30	2.36 2.88 5.46 2.13 3.03 4.59 5.46 5.44 2.50 5.24 5.24 5.24 5.24 4.50 5.24 4.50 5.24 4.51 3.389 3.89 3.235 3.1457 100.000 0.88 2.550 1.107 0.887 2.555 5.54 5.556 5.556 5.5575 5.5575 5.5575 5.5575 5.5575 5.5575 5.5575 5.5575 5.5575 5.55755 5.55755 5.55755555555
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U He B Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu T Liu S Col Liu F Chan G Gin C Zheng M Wan S Liu Z Xu B Sun Y He R	March March March April April April April April May May May July August August August August August August August August August August August August August Discomber October October October October October November December I = 92.6%, p = 0.000) March March March March March March April April April April April April April April April April August	196, 10 (172, 22, 28, 98) 196, 10 (172, 22, 28, 98) 198, 33 (109, 25, 25, 42) 198, 33 (109, 25, 25, 42) 198, 33 (109, 25, 25, 42) 198, 33 (109, 25, 25, 42) 199, 00 (182, 82, 15, 12) 199, 00 (182, 82, 15, 12) 177, 32 (14, 35, 340, 31) 222, 33 (113, 74, 146, 39) 177, 100 (143, 92, 172, 80) 199, 00 (178, 82, 712, 88) 175, 47 (140, 78, 210, 16) 199, 00 (178, 82, 712, 88) 117, 100 (143, 92, 172, 88) 116, 00 (111, 76, 188, 24) 117, 100 (143, 92, 172, 88) 116, 00 (111, 76, 188, 24) 117, 100 (143, 92, 172, 88) 116, 07 (112, 77, 210, 56) 128, 200 (182, 00, 181, 80) 116, 07 (112, 77, 210, 56) 127, 33 (113, 54, 168, 80) 116, 07 (113, 82, 201, 16) 127, 09 (163, 06, 191, 11) 102, 00 (112, 00, 153, 131, 07) 125, 30 (113, 82, 268, 81) 114, 60 (24, 30, 207, 20) 125, 30 (113, 82, 268, 81) 114, 60 (24, 30, 207, 20) 125, 30 (113, 82, 268, 81) 126, 207, 103, 103, 103, 103) 127, 29 (163, 06, 191, 11) 128, 30 (112, 20, 155, 10) 98, 42 (79, 81, 100, 55) 128, 30 (113, 86, 268, 81) 127, 62 (143, 103, 156, 52) 199, 33 (131, 88, 268, 81) 199, 33 (131, 88, 268, 81) 1	2.36 5.46 2.13 3.03 5.45 5.45 5.44 4.45 5.00 2.60 5.24 5.24 4.21 5.00 2.60 5.24 4.20 5.24 4.21 3.89 7.41 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 5.24 5.24 5.24 5.24 5.24 5.24 5.24
Chen G Oin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Subtotal (I-squares d'Alessandro M Jin XH Cai L S Subtotal (I-squares Chen G Oin C Zheng M Wan S Liu Z Liu Z Sub Y He R Sub Y He R Sub Y He R Sub Y He R Zhang X Jiang M	March March March April April April April June July August August August August August August August August August September October November December December I= 92.6%, p = 0.000) March	196, 10 (127 22, 264, 98) 196, 10 (127 22, 264, 98) 196, 20 (127 22, 264, 98) 193, 33 (108, 26, 153, 22, 28) 193, 33 (108, 26, 153, 22, 28) 330, 71 (278, 30, 384, 52) 194, 30 (118, 72, 177, 80) 199, 00 (128, 28, 151, 12) 273, 32 (14, 35, 40, 31) 222, 33 (113, 74, 146, 52) 171, 00 (149, 30, 118, 27) 172, 00 (117, 16, 116, 52) 174, 104, 29, 121, 104 194, 20 (117, 27, 168, 24) 194, 20 (112, 27, 374, 47) 194, 20 (118, 28, 121, 104) 194, 20 (112, 27, 121, 104) 194, 20 (112, 28, 118, 24) 194, 20 (112, 28, 121, 104) 194, 20 (113, 28, 222, 16) 1144, 20 (112, 30, 207, 30) 1125, 30 (115, 56, 108, 114, 104) 1123, 30 (112, 56, 108, 114) 1123, 30 (112, 56, 108, 114) 1123, 30 (112, 56, 108, 114) 1133, 31 (112, 76, 268, 81) 1143, 31 (112, 76, 268, 81) 1153, 30 (112, 56, 163, 104) 1153, 30 (112, 56, 163, 104) 1154, 30 (112, 56, 164, 104) 1154, 30	2.36 2.48 5.46 2.13 3.03 5.45 5.45 5.44 4.42 5.10 5.24 4.42 5.10 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.24 4.21 5.26 5.26 5.24 5.26 5.26 5.26 5.26 5.26 5.26 5.26 5.26
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L U F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu S Jin XH Cai L Yi P Subtolal (I-squared Chen G Chen G Chen G Chen G Chen G Sur C Zheng M Wan Y He R Sun Y Liu Z Xu B Sun Y He R Liu Z Xu B Sun Y He R He R Liu Z Xu B Sun Y He R He R He R He R He R He R He R He R	March March March April April April May May May May May May May July August August August August September October October October October October March April April April April April April Augu	196, 10 (172, 22, 84, 98) 196, 10 (172, 22, 84, 98) 193, 31 (192, 52, 52, 42) 193, 33 (192, 52, 52, 42) 193, 33 (192, 52, 52, 42) 226, 67 (203, 7, 22, 29) 330, 71 (274, 90, 384, 52) 183, 30 (192, 72, 175, 08) 199, 00 (182, 88, 215, 12) 177, 30 (143, 38) (119, 72, 175, 08) 199, 00 (182, 88, 215, 12) 177, 00 (143, 30, 192, 70) 125, 67 (202, 11, 185, 22) 144, 33 (127, 90, 160, 76) 157, 00 (141, 32, 172, 38) 156, 00 (111, 76, 188, 24) 126, 457 (142, 78, 210, 16) 128, 20 (147, 55, 188, 85) 161, 67 (112, 77, 210, 56) 227, 33 (185, 61, 288, 06) 157, 00 (132, 20, 181, 90) 177, 09 (163, 06, 191, 11) 184, 20 (175, 56, 181, 90) 177, 09 (163, 06, 191, 11) 184, 20 (175, 56, 181, 90) 177, 09 (163, 06, 191, 11) 184, 20 (175, 56, 181, 90) 177, 09 (163, 06, 191, 11) 184, 20 (175, 56, 181, 90) 177, 09 (163, 06, 191, 11) 184, 20 (125, 06, 151, 10) 184, 33 (134, 110, 41) 184, 33 (134, 110, 41) 184, 33 (134, 110, 41) 184, 33 (134, 110, 41) 184, 33 (134, 110, 43) 183, 33 (134, 224, 48) 194, 33 (134, 224, 10) 194, 33 (134, 224, 48) 194, 33 (134, 124, 10) 194, 33 (134, 10, 28) 194, 33 (134, 10, 28) 194, 33 (134, 224, 10) 194, 30 (14,	2.36 2.88 5.46 4.59 3.03 4.42 5.10 5.24 4.42 5.00 5.24 4.42 5.03 5.08 5.13 5.08 5.13 5.08 5.13 5.09 3.29 4.24 4.65 5.389 7.23 7.20 5.25 9.723
Chen G Qin C Qin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L U S U L U F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Cai L Yi P Severe Chen G Qin C Zheng M Wan S Liu Z Zheng M Wan S Liu Z Zhang X Zhang X Xhang X	March March March April August August August August August Colober October October October December December December March March March March April August	196, 10 (172 22, 28, 49) 196, 10 (172 22, 28, 49) 193, 33 (186, 25, 258, 42) 193, 33 (186, 25, 258, 42) 193, 33 (185, 258, 42) 193, 30, 71 (276, 80), 384, 52) 184, 80 (1187, 27, 176, 80) 199, 00 (182, 88, 215, 12) 277, 33 (143, 53, 48), 011 223, 33 (113, 74, 146, 83) 177, 00 (143, 30, 172, 73) 188, 24) 194, 30 (172, 74, 188, 24) 195, 200 (112, 75, 188, 24) 195, 200 (112, 75, 188, 24) 195, 200 (112, 74, 188, 24) 195, 200 (112, 74, 186, 26) 195, 200 (112, 75, 188, 24) 195, 200 (112, 75, 188, 24) 195, 200 (112, 74, 186, 24) 195, 200 (112, 75, 106, 76) 195, 200 (112, 75, 106, 76) 195, 200 (112, 75, 106, 76) 195, 200 (112, 75, 108, 24) 195, 33 (134, 86, 268, 81) 195, 767 (64, 43, 110, 91) 194, 33 (134, 41, 116, 85) 198, 33 (134, 21, 22) 199, 33 (134, 22, 22, 46) 104, 00 (155, 212, 22, 46) 104, 00 (12, 22, 12, 26) 104, 00 (12, 22, 12,	2.36 2.88 2.88 2.13 3.03 4.42 5.10 5.04 4.42 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.21 5.00 5.24 4.22 5.00 5.25 5.25 5.25 5.25 5.25 5.25 5
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L W F U U F Liu F Liu F Liu F Liu F Liu F Liu F Liu T Cai L Y P Subtotal (I-squared Chen G Qin C Zheng M Wan S Liu Z Sun Y He R Subtotal (I-squared Chen G Qin C Zheng M Wan S Liu Z Sun Y He R Sun Y He R Zhang X Jiang X J	March March March April April April May May May July July August August August August August October October October October October August March March March March March March April August	196, 10 (172, 22, 28, 49) 196, 10 (172, 22, 28, 49) 198, 23 (192, 52, 52, 42) 198, 33 (198, 52, 52, 42) 198, 33 (198, 52, 52, 42) 198, 33 (198, 52, 52, 42) 198, 33 (192, 42, 59) 199, 00 (182, 88, 151, 12) 177, 100 (143, 30, 112, 77, 16, 89) 199, 00 (182, 88, 151, 12) 177, 00 (143, 30, 112, 77, 114, 53) 177, 00 (143, 30, 112, 77, 114, 53) 177, 00 (143, 22, 77, 28, 64) 199, 00 (111, 78, 188, 29) 165, 70 (141, 162, 172, 38) 166, 70 (163, 139, 67) 177, 00 (143, 22, 77, 28) 166, 70 (143, 20, 116, 69) 177, 90 (143, 06, 191, 11) 186, 70 (143, 20, 27, 50) 186, 50 (145, 52, 22, 16) 114, 60 (213, 02, 75, 50) 199, 33 (113, 44, 30, 65) 128, 30 (119, 52, 116, 70) 128, 30 (119, 52, 116, 70) 128, 30 (119, 52), 113, 70) 128, 30 (119, 52), 114, 77, 164, 78, 11, 90) 177, 90 (163, 06, 191, 11) 187, 67 (164, 43, 110, 51) 199, 33 (113, 44, 20) 199, 33 (114, 48, 30) 199, 33 (114, 48, 30) 199, 33 (71, 44, 118, 30) 197, 57 (164, 48, 110, 51) 199, 33 (71, 44, 118, 30) 197, 57 (164, 48, 110, 51) 199, 33 (71, 44, 118, 30) 197, 37 (164, 38, 112, 72) 199, 33 (71, 44, 118, 30) 197, 37 (164, 48, 30) 198, 37 (144, 418, 30) 199, 33 (71, 44, 118, 30) 193, 37 (134, 418, 30) 193, 37 (144, 418, 30) 194, 37 (144, 418, 30) 194, 37 (144, 418, 30) 194, 37 (144, 418, 3	2.36 2.88 5.46 4.59 3.03 4.42 5.10 5.24 4.42 5.00 5.24 4.44 5.00 5.24 4.41 5.08 5.13 5.08 5.13 5.08 5.13 5.08 5.14 7.00 2.35 3.14 4.65 5.39 4.24 4.65 5.39 4.24 5.59 5.59 5.59 5.59 5.59 5.59 5.55 5.59
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Hen R Zhang X Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L U S U L U F Liu F Liu F Liu F Liu F Liu Z Liu X U X U X Zou L Zou D Zheng M Wan S Liu Z Zheng M Wan S Liu Z Zhang X Zhang X Zheng M Liu Z Zhang X Zheng M Liu Z Zheng M Liu Z Zhang X Zhang X Xhang Xhang Xhang Xhang Xhang Xhang Xhang Xhang Xh	March March March April August August August August August August October October October November December March March March March March April August	196, 10 (172, 22, 24, 94) 196, 10 (172, 22, 24, 94) 196, 20 (175, 22, 24, 94) 193, 33 (108, 95, 126, 22) 193, 33 (108, 95, 126, 22) 193, 33 (108, 25, 258, 42) 226, 57 (200, 37, 262, 96) 303, 07 (1276, 90, 384, 52) 184, 30 (118, 72, 173, 08) 199, 00 (128, 84, 515, 12) 277, 33 (141, 35, 40, 31) 222, 33 (121, 70, 144, 93) 171, 00 (149, 30, 192, 70) 125, 677 (224, 1158, 24) 174, 33 (112, 74, 146, 93) 177, 00 (141, 62, 172, 38) 175, 00 (111, 76, 188, 24) 126, 200 (1112, 77, 188, 24) 126, 200 (112, 76, 188, 24) 126, 200 (112, 76, 188, 24) 127, 33 (185, 61, 188, 24) 126, 200 (112, 76, 188, 24) 126, 200 (112, 70, 188, 24) 127, 33 (185, 61, 128, 24) 128, 00 (115, 55, 120, 24) 128, 30 (122, 20, 151, 100) 125, 30 (115, 51, 100) 125, 30 (112, 52, 116, 20) 125, 30 (112, 53, 103, 77) 132, 10 (70, 61, 138, 56) 111, 00 (115, 55, 221, 155, 10) 94, 677 (794, 11, 103) 194, 33 (13, 44, 30) 125, 30 (138, 26, 86, 11) 194, 33 (138, 26, 86, 11) 194, 33 (138, 26, 11) 194, 33 (1138, 26, 86, 11) 194, 33 (114, 26	2.36 2.38 5.48 5.45 9.303 5.45 9.303 5.44 4.50 5.24 4.42 5.00 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.24 4.20 5.23 5.25 5.39 7.23 5.39 9.424 6.65 5.39 7.23 5.97 5.97 5.97 5.97 5.97 5.97 5.97 5.97
Chen G Qin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Zhang X Zhang X Zhang X Jiang M Li S Wu Y Han M Zou L W F U U F Liu F Liu F Liu F Liu F Liu F Liu F Liu T Cai L Y P Subtotal (I-squared Chen G Qin C Zheng M Wan S Liu Z Sun Y He R Subtotal (I-squared Chen G Qin C Zheng M Wan S Liu Z Sun Y He R Sun Y He R Zhang X Jiang X J	March March March April April April May May May July July August August August August August October October October October October August March March March March March March April August	196, 10 (172, 22, 28, 49) 196, 10 (172, 22, 28, 49) 198, 33 (196, 25, 254, 42) 198, 33 (197, 27, 180, 984, 254, 45) 199, 00 (112, 28, 151, 12) 177, 30 (143, 54, 118, 52) 144, 33 (127, 73, 124, 154, 54) 177, 00 (141, 22, 17, 26, 184, 59) 150, 00 (111, 27, 17, 26, 184, 59) 164, 70 (143, 192, 17, 27, 20, 16) 126, 20 (142, 50, 163, 130, 97) 126, 20 (142, 20, 161, 20) 177, 99 (163, 06, 191, 11) 177, 99 (163, 06, 191, 11) 184, 33 (153, 27, 126, 184, 59) 114, 400 (113, 45, 222, 15) 114, 400 (113, 45, 22) 112, 230 (113, 46, 268, 81) 127, 79 (163, 26, 119, 11) 127, 79 (163, 06, 191, 11) 128, 80 (102, 50, 155, 10) 94, 47 (77, 81, 110, 31) 94, 33 (174, 41, 108, 31) 88, 33 (153, 82, 122, 49) 104, 00 (85, 52, 122, 49) 103, 75 (863, 81, 418, 30) 127, 88 (7168, 41, 418, 30) 127, 88 (7168, 414, 410, 41) 128, 717	2.36 2.88 5.46 4.59 3.03 4.42 5.10 5.24 4.42 5.00 5.24 4.44 5.00 5.24 4.41 5.08 5.13 5.08 5.13 5.08 5.13 5.08 5.14 7.00 2.35 3.14 4.65 5.39 4.24 4.65 5.39 4.24 5.59 5.59 5.59 5.59 5.59 5.59 5.55 5.59
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y Sun Y He R Zhang X Zhang X Zhang X Li S Wu Y Han M Zou L U U U X Liu F Liu F Liu F Liu F Liu F Liu F Liu F Cai L V A Man M Zou L Chen G Gin C Zheng M Wan S Liu Z Liu Z Subtotal (I-squared Chen G Gin C Zheng M Wan S Liu Z Liu Z Liu Z Subtotal (I-squared M Subtotal (I-squared M M Subtotal (I-squared M M Subtotal (I-squared M M Subtotal (I-squared M M M Subtotal (I-squared M M M Subtotal (I-squared M M M M M Subtotal (I-squared M M M M M M M M M M M M M	March March March March April April April May May May May May July August August August August October October October October October August April April April April April April August August August August August August August August August <	196, 10 (172, 22, 28, 49) 196, 10 (172, 22, 28, 49) 196, 20 (175, 20, 25, 42) 198, 33 (109, 25, 25, 42) 198, 33 (109, 25, 25, 42) 198, 33 (109, 25, 25, 42) 198, 30 (119, 27, 176, 09) 199, 00 (128, 82, 15, 12) 173, 32 (14, 35, 340, 31) 222, 33 (119, 74, 149, 39) 171, 100 (149, 30, 192, 70) 175, 47 (140, 73, 210, 16) 175, 47 (140, 73, 210, 16) 175, 47 (140, 73, 210, 16) 126, 200 (112, 68, 26) 165, 700 (114, 28, 211, 29) 175, 47 (140, 73, 210, 16) 126, 200 (112, 68, 20, 210, 10) 177, 09 (163, 06, 19), 11) 176, 77 (140, 73, 210, 16) 177, 09 (163, 06, 19), 11) 176, 77 (140, 73, 210, 16) 177, 09 (163, 06, 19), 11) 177, 09 (163, 06, 19), 11) 176, 77 (140, 73, 210, 16) 177, 09 (163, 06, 19), 11) 177, 09 (163, 06, 19), 11) 177, 09 (163, 06, 19), 11) 177, 09 (163, 06, 19), 11) 178, 77 (140, 73, 210, 16) 177, 09 (163, 06, 19), 11) 177, 09 (163, 06, 19), 11) 183, 39 (138, 226, 81) 199, 33 (131, 82, 204, 10) 199, 33 (131, 82, 204, 10) 103, 75 (88, 83, 121, 22) 103, 67 (88, 82, 122, 204) 103, 37 (78, 82, 214) 103, 37 (78, 82, 214) 104, 33 (77, 77, 22, 24) 105, 37 (78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 78, 77, 7	2.36 2.88 5.46 2.13 3.03 2.80 5.45 5.46 5.44 5.06 5.24 5.24 5.24 5.24 5.24 5.24 5.24 5.24
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Zhang X Li S Wu Y He B Li S Wu Y He B Li S Li S U F Liu S Subtotal (I-squared Chen G Gin C Cai L Yi P Subtotal (I-squared Zheng M Liu Z Zheng M He R Zheng M Liu Z Zheng M Liu Z Zheng M Liu Z Zheng M Liu Z Liu S Subtotal (I-squared Zheng M Liu Z Liu S Subtotal (I-squared Zheng M Liu Z Liu S Subtotal (I-squared Zheng M Liu Z Liu S Liu Z Liu S Liu Z Liu S Liu S	March March March April April April May May May May May May July August August August August August Saptember October October December December August March March March March March March March April April April August August August August August <tr< td=""><td>196, 10 (172, 22, 84, 96) 196, 10 (172, 22, 84, 96) 196, 20 (172, 22, 84, 96) 193, 33 (108, 65, 253, 42) 226, 57 (203, 73, 262, 96) 330, 71 (278, 90, 384, 52) 183, 33 (103, 72, 172, 80) 199, 00 (182, 88, 151, 12) 273, 33 (113, 74, 146, 93) 171, 00 (194, 93), 182, 70) 199, 00 (182, 84, 154, 154, 154, 154, 154, 154, 154, 15</td><td>2.36 2.88 5.48 5.45 4.59 4.42 5.10 5.26 5.24 4.50 5.26 5.24 4.21 5.09 5.24 4.21 5.09 5.24 4.21 5.09 5.24 4.21 5.09 5.389 1.07 4.24 4.67 3.29 2.35 3.389 1.07 5.25 5.39 7.22 5.39 7.25 7.25 7.25 7.25 7.25 7.25 7.25 7.25</td></tr<>	196, 10 (172, 22, 84, 96) 196, 10 (172, 22, 84, 96) 196, 20 (172, 22, 84, 96) 193, 33 (108, 65, 253, 42) 226, 57 (203, 73, 262, 96) 330, 71 (278, 90, 384, 52) 183, 33 (103, 72, 172, 80) 199, 00 (182, 88, 151, 12) 273, 33 (113, 74, 146, 93) 171, 00 (194, 93), 182, 70) 199, 00 (182, 84, 154, 154, 154, 154, 154, 154, 154, 15	2.36 2.88 5.48 5.45 4.59 4.42 5.10 5.26 5.24 4.50 5.26 5.24 4.21 5.09 5.24 4.21 5.09 5.24 4.21 5.09 5.24 4.21 5.09 5.389 1.07 4.24 4.67 3.29 2.35 3.389 1.07 5.25 5.39 7.22 5.39 7.25 7.25 7.25 7.25 7.25 7.25 7.25 7.25
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y He R Zhang X Zhang X Li S Wu Y Han M Zou L Lu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Cai L X Severe Chen G Gin C Zheng M Wan S Liu Z Liu Z Liu Z Liu Z Liu Z Liu F Subtotal (I-squares Chen G Gin C Zheng M Wan S Liu Z Liu Z Liu Z Liu Z Subtotal (I-squares Chen G Gin C Zheng M Wan S Liu Z Liu Z L	March March March April August August August August August Catober October October October October November December april April April April April April April August	196, 10 (172, 22, 24, 98) 196, 10 (172, 22, 24, 98) 198, 33 (102, 55, 254, 42) 198, 33 (102, 55, 254, 42) 198, 33 (102, 55, 254, 42) 198, 30 (112, 72, 176, 60) 199, 00 (112, 82, 171, 12, 12) 199, 00 (112, 82, 173, 44, 97) 199, 00 (112, 82, 172, 88) 199, 00 (112, 82, 172, 88) 111, 00 (114, 818, 24) 1175, 47 (140, 78, 210, 16) 1126, 00 (114, 62, 172, 88) 114, 60 (213, 03, 277, 64) 1177, 09 (113, 82, 116, 90) 1177, 09 (113, 82, 100, 113, 100) 1128, 100, 113, 180, 208, 110) 127, 00 (113, 82, 116, 90) 1177, 09 (113, 80, 105, 110) 128, 33 (113, 84, 116, 83) 118, 118, 248, 81, 110) 199, 33 (113, 84, 116, 83) 118, 33 (138, 21, 224) 108, 57 (184, 91, 110) 199, 33 (113, 84, 116, 83) 118, 33 (138, 21, 224) 109, 33 (138, 21, 224) 100, 33 (163, 21, 122) 100, 633 (163, 21, 122, 124) 103, 37 (168, 81, 110) 102, 33 (153, 82, 122, 24) 103, 37 (168, 81, 110) 102, 33 (153, 82, 122, 24) 103, 33 (153, 82, 122, 24) 104, 57 (184, 17, 110) 102, 30, 107, 122, 107, 102, 109, 123, 110) 102, 107, 113, 100, 113, 110, 11	2.36 2.88 5.44 2.13 3.03 2.80 4.42 5.00 5.24 5.24 5.24 5.24 5.24 5.24 5.24 5.24
Chen G Qin C Qin C Qin C Qin C Qin C Sin Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Sun Y Li Z Zhang X Zhang X Li S Uu F Li S Uu F Li S Li S Uu F Li S Li S Jin XH Cai L Yi P Subtotal (I-squared Chen G Qin C Zheng M Wan S Sun Y He R Sub Sun Y He R Sub Sun Y He R Sub Sun Y Li S Li Z Sub Sun Y He R Sub Sun Y Li S Li Z Li S Sun Y He R Li S Li S Sun Y He R Li S Li	March March March April April April April April May May June July August August August August August August August Cotober October October October October October October October August August August August August August August August August November December March Marc	196, 10 (172, 22, 84, 96) 196, 10 (172, 22, 84, 96) 196, 20 (172, 22, 84, 96) 193, 33 (108, 26, 158, 32) 193, 33 (108, 26, 158, 32) 193, 30 (17, 172, 169) 199, 00 (182, 88, 151, 12) 273, 214, 35, 340, 31) 223, 32 (137, 34, 146, 95) 171, 00 (149, 30, 192, 70) 125, 67 (92, 81, 168, 52) 175, 700 (141, 26, 172, 36) 199, 00 (112, 27, 374, 47) 175, 700 (141, 26, 172, 36) 199, 00 (112, 27, 374, 47) 175, 700 (141, 26, 123, 39) 110, 00 (111, 75, 188, 24) 254, 57 (132, 67, 210, 16) 128, 00 (111, 03, 139, 97) 128, 200 (182, 00, 211, 10) 273, 33 (185, 41, 280, 06) 157, 00 (122, 00, 188, 26) 117, 790 (183, 06, 191, 11) 110, 00 (115, 155, 222, 15) 114, 460 (213, 207, 56) 112, 200 (122, 00, 181, 80) 117, 790 (183, 06, 191, 11) 112, 107, 761, 118, 35) 113, 33 (113, 44, 30, 103, 52) 128, 33 (112, 44, 30, 103, 52) 128, 33 (172, 212, 46) 108, 33 (172, 22, 29) 104, 30 (185, 22, 214, 41) 104, 30 (115, 35, 60, 60) 117, 777 (46, 144, 10) 117, 777 (41, 12, 171, 12) 117, 777 (46, 144, 10) 117, 777 (41, 12, 171, 12) 117, 777 (41, 12, 171, 12) 113, 78, 77, 78, 78, 78, 78, 78, 79, 79, 78, 78, 78, 78, 79, 79, 78, 79, 78, 78, 78, 78, 78, 78, 78, 78, 78, 78	2.36 2.88 5.46 2.13 3.03 4.59 3.03 5.45 4.42 5.10 5.26 6.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8
Chen G Gin C Zheng M Wan S Liu Z Xu B Sun Y Sun Y He R Zhang X Zhang X Zhang X Liu S Wu Y Han M Zu L U S Wu Y He R Liu F Liu F Liu F Liu F Liu F Liu F Liu F Liu F Cai L Yi P Subtolal (I-squared Yi P Subtolal (I-squared Jin XH Cai L Yi P Subtolal (I-squared Jin XH Cai L Yi P Subtolal (I-squared Jin XH He R Zhang X Jin XH He R He R He R He R He R He R He R He R He R He R HA HA HA HA HA HA HA HA HA HA HA HA	March March March April August August August August August Catober October October October October November December april April April April April April April August	196, 10 (172, 22, 24, 98) 196, 10 (172, 22, 24, 98) 198, 33 (102, 55, 254, 42) 198, 33 (102, 55, 254, 42) 198, 33 (102, 55, 254, 42) 198, 30 (112, 72, 176, 60) 199, 00 (112, 82, 171, 12, 12) 199, 00 (112, 82, 173, 44, 97) 199, 00 (112, 82, 172, 88) 199, 00 (112, 82, 172, 88) 111, 00 (114, 818, 24) 1175, 47 (140, 78, 210, 16) 1126, 00 (114, 62, 172, 88) 114, 60 (213, 03, 277, 64) 1177, 09 (113, 82, 116, 90) 1177, 09 (113, 82, 100, 113, 100) 1128, 100, 113, 180, 208, 110) 127, 00 (113, 82, 116, 90) 1177, 09 (113, 80, 105, 110) 128, 33 (113, 84, 116, 83) 118, 118, 248, 81, 110) 199, 33 (113, 84, 116, 83) 118, 33 (138, 21, 224) 108, 57 (184, 91, 110) 199, 33 (113, 84, 116, 83) 118, 33 (138, 21, 224) 109, 33 (138, 21, 224) 100, 33 (163, 21, 122) 100, 633 (163, 21, 122, 124) 103, 37 (168, 81, 110) 102, 33 (153, 82, 122, 24) 103, 37 (168, 81, 110) 102, 33 (153, 82, 122, 24) 103, 33 (153, 82, 122, 24) 104, 57 (184, 17, 110) 102, 30, 107, 122, 107, 102, 109, 123, 110) 102, 107, 113, 100, 113, 110, 11	2.36 2.88 5.44 2.13 3.03 2.60 5.24 5.04 5.24 5.04 5.24 5.04 5.24 5.04 5.24 5.04 5.24 5.05 5.24 5.04 5.24 5.05 5.24 5.05 5.23 1.05 5.23 1.05 5.23 1.00 5.23 1.00 5.24 5.23 1.00 5.24 5.23 5.23 1.25 7.23 3.14 7.57 7.19 7.24 8.05 5.05

Figure 5. The forest plot of pooled effect on the standardized mean difference (SMD) of B cell between non-severe and severe groups (a) and average B cell count in non-severe and severe groups (b).





100

200

1 300

400

Novembe Novembe December red = 87.0%, p = 0.000)

NOTE: Weights are from random effects analysis

al (I-sq

and ongoing critical trials on COVID-19 outcome; thus, further studies on severe patients, especially those who suffer from cytokine storm and ARDS(acute respiratory distress syndrome), are needed to elucidate the association between these determinants and COVID-19 severity or mortality. Furthermore, the sample population of some studies was small that may decrease the power of the studies. Finally, most of them were carried out in China, and measurements may have biased populations.

Conclusion

A severe type of COVID-19 may compromise the function and decrease the number of lymphocyte subsets. Thus, it is essential to identify prognostic inflammatory indicators, especially lymphocyte counts, to predict the disease severity and hospitalization. The current systematic review and meta-analysis indicated that severe COVID-19 cases had significantly lower lymphocyte counts, including CD4+ and CD8+ T cell, natural killer and B cells, than nonsevere patients. COVID-19 outcome may be complicated by lymphopenia because over-activation of lymphocytes may result in cytokine storm or ARDS. On the other hand, lymphopenia may increase SARS-CoV-2 viral load and the intensity of COVID-19. Therefore, novel therapeutic strategies such as targeting lymphocyte proliferation or contraction (IL-7 and PD1/PD-L1 inhibitors, respectively) may help retrieve lymphocyte counts in patients with severe COVID-19.

Authors' contribution

AK, HD, and HA were the principal investigators of the study. HD and HA were included in preparing the concept and design. HD, HA, and PP managed the analyses of the study. All authors participated in preparing the final draft of the manuscript, revised the manuscript and critically evaluated the intellectual contents. All authors have read and approved the content of the manuscript and confirmed the accuracy or integrity of any part of the work.

Conflicts of interest

The authors declare that they have no conflict of interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication and double publication) were completely observed by the authors.

Funding/Support

None.

Reference

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. doi: 10.1056/NEJMoa2001017.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet. 2020;395:1054-1062. doi: 10.1016/S0140-6736(20)30566-3
- McKechnie JL, Blish CA. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? Cell Host Microbe. 2020;27:863-9. doi: 10.1016/j.chom.2020.05.009.
- 4. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al.

Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-9. doi: 10.1172/JCl137244.

- Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta. 2020;508:110-14. doi: 10.1016/j. cca.2020.05.019.
- Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020;81:e51-60. doi: 10.1016/j.jinf.2020.04.012.
- Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146:119-127.e4. doi: 10.1016/j. jaci.2020.04.027.
- Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146:89-100. doi: 10.1016/j.jaci.2020.05.003.
- Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583:437-440. doi: 10.1038/s41586-020-2355-0.
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762-8. doi: 10.1093/cid/ciaa248.
- 11. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533-5. doi: 10.1038/ s41423-020-0402-2.
- 12. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19. Viral Immunol. 2021;34:330-5. doi: 10.1089/vim.2020.0062.
- Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189:428-37. doi: 10.1111/ bjh.16659.
- 14. Yang P, Wang P, Song Y, Zhang A, Yuan G, Cui Y. A retrospective study on the epidemiological characteristics and establishment of an early warning system of severe COVID-19 patients. J Med Virol. 2020;92:2173-80. doi: 10.1002/jmv.26022.
- Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, et al. T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019. J Infect Dis. 2020;222:198-202. doi: 10.1093/infdis/jiaa252.
- Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect. 2020;81:318-356. doi: 10.1016/j. jinf.2020.03.054.
- 17. Wei YY, Wang RR, Zhang DW, Tu YH, Chen CS, Ji S, et al. Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81:e89-e92. doi: 10.1016/j.jinf.2020.04.010.
- Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020;112:102473. doi: 10.1016/j.jaut.2020.102473.
- He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020;127:104361. doi: 10.1016/j. jcv.2020.104361.

- Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201:1380-8. doi: 10.1164/ rccm.202002-0445OC.
- Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study. J Infect. 2020;81:318-56. doi: 10.1016/j. jinf.2020.04.006.
- 22. Li S, Jiang L, Li X, Lin F, Wang Y, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5:e138070. doi: 10.1172/jci.insight.138070.
- 23. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92:2067-73. doi: 10.1002/jmv.25972.
- 24. Li X, Liu Y, Li J, Sun L, Yang J, Xu F, et al. Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2. Immunol Res. 2020;68:398-404. doi: 10.1007/s12026-020-09156-2.
- Han M, Xu M, Zhang Y, Liu Z, Li S, He T, et al. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med Microbiol Immunol. 2020;209(6):657-68. doi: 10.1007/s00430-020-00693-z.
- Liu J, Liu Z, Jiang W, Wang J, Zhu M, Song J, et al. Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalized patients from Wuhan, China. Clin Respir J. 2021;15:293-309. doi: 10.1111/crj.13296.
- Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC Infect Dis. 2020;20:787. doi: 10.1186/s12879-020-05452-2.
- Kalpakci Y, Hacibekiroglu T, Trak G, Karacaer C, Demirci T, Kocayigit H, et al. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker. Rev Assoc Med Bras (1992). 2020;66:1666-72. doi: 10.1590/1806-9282.66.12.1666.
- 29. Zou L, Dai L, Zhang Y, Fu W, Gao Y, Zhang Z, et al. Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients With Coronavirus Disease 2019 in Wuhan, China. Front Med (Lausanne). 2020;7:532. doi: 10.3389/ fmed.2020.00532.
- He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y, et al. The Metabolic Changes and Immune Profiles in Patients With COVID-19. Front Immunol. 2020;11:2075. doi: 10.3389/ fimmu.2020.02075.
- Wu Y, Huang X, Sun J, Xie T, Lei Y, Muhammad J, et al. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19. mSphere. 2020;5:e00362-20. doi: 10.1128/ mSphere.00362-20.
- 32. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-943. doi: 10.1001/jamainternmed.2020.0994.
- Chen J, Han T, Huang M, Yang Y, Shang F, Zheng Y, et al. Clinical characteristics of asymptomatic carriers of novel coronavirus disease 2019: A multi-center study in Jiangsu Province. Virulence. 2020;11:1557-68. doi: 10.1080/21505594.2020.1840122.
- Zhou YH, Li H, Qin YY, Yan XF, Lu YQ, Liu HL, et al. Predictive factors of progression to severe COVID-19. Open Med (Wars). 2020;15:805-814. doi: 10.1515/med-2020-0184.
- 35. Jin XH, Zhou HL, Chen LL, Wang GF, Han QY, Zhang JG, et

al. Peripheral immunological features of COVID-19 patients in Taizhou, China: A retrospective study. Clin Immunol. 2021;222:108642. doi: 10.1016/j.clim.2020.108642.

- 36. Yi P, Yang X, Ding C, Chen Y, Xu K, Ni Q, et al. Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study. BMC Infect Dis. 2020;20:943. doi: 10.1186/s12879-020-05682-4.
- XieL, WuQ, LinQ, LiuX, LinW, HaoS, etal. Dysfunction of adaptive immunity is related to severity of COVID-19: a retrospective study. Ther Adv Respir Dis. 2020;14:1753466620942129. doi: 10.1177/1753466620942129.
- Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Sci Rep. 2020;10:13689. doi: 10.1038/s41598-020-70387-2.
- d'Alessandro M, Bergantini L, Cameli P, Curatola G, Remediani L, Sestini P, et al. Peripheral biomarkers' panel for severe COVID-19 patients. J Med Virol. 2021;93:1230-2. doi: 10.1002/jmv.26577.
- Wang A, Gao G, Wang S, Chen M, Qian F, Tang W, et al. Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. Med Sci Monit. 2020;26:e925974. doi: 10.12659/MSM.925974.
- 41. Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2020;8:1145. doi: 10.21037/atm-20-5479.
- Cai L, Zhou X, Wang M, Mei H, Ai L, Mu S, et al. Predictive Nomogram for Severe COVID-19 and Identification of Mortality-Related Immune Features. J Allergy Clin Immunol Pract. 2021;9:177-184.e3. doi: 10.1016/j.jaip.2020.10.043.
- 43. Shokraee K, Mahdavi H, Panahi P, Seirafianpour F, Jahromizadeh AM, Tofighi R, et al. Accuracy of chest computed tomography and reverse transcription polymerase chain reaction in diagnosis of 2019 novel coronavirus disease; a systematic review and metaanalysis. Immunopathol Persa. 2021;7(2):e36. doi:10.34172/ipp.2021.36.
- 44. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:157. doi: 10.3389/fmolb.2020.00157.
- Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864-877.e5. doi: 10.1016/j. immuni.2020.07.026.
- Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020;221:1762-9. doi: 10.1093/infdis/jiaa150.
- Liu K, Yang T, Peng XF, Lv SM, Ye XL, Zhao TS, et al. A systematic meta-analysis of immune signatures in patients with COVID-19. Rev Med Virol. 2021;31(4):e2195. doi: 10.1002/ rmv.2195.
- Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):e137799. doi: 10.1172/jci.insight.137799.
- 49. Zheng Y, Huang Z, Yin G, Zhang X, Ye W, Hu Z, Hu C, et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. medrxiv. 2020. doi: 10.1101/2020.02.19.20024885.
- 50. Li D, Long Y, Huang P, Guo W, Wu S, et al. Clinical

characteristics of 80 patients with COVID-19 in Zhuzhou City. Chin J Infect Control. 2020;19:227-33.

- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382:1199-1207. doi: 10.1056/NEJMoa2001316.
- 52. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and metaanalysis. J Intensive Care. 2020;8:36. doi: 10.1186/s40560-020-00453-4.
- 53. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20:529-36. doi: 10.1038/ s41577-020-0402-6.
- 54. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. MedRxiv. 2020. doi: 10.1101/2020.02.17.20024166.
- 55. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:

immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2.

- Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-432. doi: 10.1002/jmv.25685.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834-847. doi: 10.1002/ajh.25829.
- Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149-163. doi: 10.1111/imr.12823.
- Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.